CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS AS DIAGNOSTIC BIOMARKERS FOR PRE-LUPUS Russian patent published in 2019 - IPC G01N33/564 G06F19/00 G01N33/49 

FIELD: biotechnology.

SUBSTANCE: claimed is a method for determining whether to classify a patient as exhibiting pre-Lupus. Method includes taking a blood sample from a patient, measuring levels for a plurality of cell-bound complement activation products (CB-CAP) in the blood sample, wherein the plurality CB-CAP includes at least eight of the following: E-C4d, E-C3d, R-C4d, R-C3d, T-C4d, T-C3d, B-C4d, B-C3d, M-C4d, M-C3d, G-C4d, G-C3d, P-C4d and E-CR1, comparing the CB-CAP levels for the patient with the control levels to determining a number of the CB-CAPs, for which the patient's levels are elevated as compared to the control levels, and considering the determined number as the possibility of classifying the patient as exhibiting pre-Lupus.

EFFECT: cell-bound complement activation products (CB-CAP) serve as diagnostic biomarkers for pre-lupus in patients who have not met at least four American College of Rheumatology (or similar, for example, SLICC) criteria for a definite Lupus diagnosis.

7 cl, 4 dwg, 7 tbl, 1 ex